Severe antibody-mediated rejection following IVIG infusion in a kidney transplant recipient with BK-virus nephropathy

Transplant Immunology

Volumn 28, Issue 4, 2013, Pages 145-147

  Mainra, R ^a   Xu, Q ^a   Chibbar, R ^a   Hassan, A ^a   Shoker, A ^a  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

Author keywords

Adverse effects; Antibody mediated rejection; BK nephropathy; Intravenous immunoglobulin; Renal transplant

Indexed keywords

BASILIXIMAB; CREATININE; HEMOGLOBIN; HLA ANTIBODY; HLA B44 ANTIGEN; HLA B7 ANTIGEN; HLA DQ ANTIGEN; HLA DQ7 ANTIGEN; HLA DR11 ANTIGEN; IMMUNOGLOBULIN G; LEFLUNOMIDE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RAPAMYCIN; TACROLIMUS; UNCLASSIFIED DRUG; UREA; IMMUNOGLOBULIN;

ACUTE KIDNEY FAILURE; ADULT; ANTIBODY MEDIATED REJECTION; ANTIBODY SPECIFICITY; ARTICLE; BK VIRUS NEPHROPATHY; CASE REPORT; CREATININE BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; GRAFT RECIPIENT; HEMODIALYSIS; HEMOGLOBIN BLOOD LEVEL; HUMAN; IMMUNOASSAY; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY BIOPSY; KIDNEY DISEASE; KIDNEY DONOR; KIDNEY FAILURE; KIDNEY GRAFT; KIDNEY GRAFT REJECTION; KIDNEY POLYCYSTIC DISEASE; NAUSEA; NEPHRECTOMY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; TACHYCARDIA; THROMBOCYTE COUNT; UREA BLOOD LEVEL; ACUTE KIDNEY INJURY; BK VIRUS; COMPLICATION; GRAFT REJECTION; IMMUNOLOGY; KIDNEY; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; MIDDLE AGED; PATHOLOGY; POLYOMAVIRUS INFECTIONS; TUMOR VIRUS INFECTIONS; VIROLOGY;

ACUTE KIDNEY INJURY; BK VIRUS; FEMALE; GRAFT REJECTION; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; KIDNEY; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; MIDDLE AGED; POLYCYSTIC KIDNEY DISEASES; POLYOMAVIRUS INFECTIONS; TUMOR VIRUS INFECTIONS;

EID: 84879839695     PISSN: 09663274     EISSN: 18785492     Source Type: Journal    
DOI: 10.1016/j.trim.2013.05.004     Document Type: Article

References (19)

1. Jordan S.C., Toyoda M., Kahwaji J., Vo A.A. Clinical aspects of intravenous immunoglobulin use in solid organ transplant recipients. Am J Transplant 2011, 11:196-202.
2. Jordan S.C., Toyoda M., Vo A.A. Intravenous immunoglobulin a natural regulator of immunity and inflammation. Transplantation 2009, 88:1-6.
3. Jordan S.C., Toyoda M., Vo A.A. Regulation of immunity and inflammation by intravenous immunoglobulin: relevance to solid organ transplantation. Expert Rev Clin Immunol 2011, 7(3):341-348.
4. Jordan S.C., Cunningham-Rundles C., McEwan R. Utility of intravenous immune globulin in kidney transplantation: efficacy, safety, and cost implications. Am J Transplant 2003, 3:653-664.
5. Sener A., House A.A., Jevnikar A.M., Boudville N., McAlister V.C., Muirhead N., et al. Intravenous immunoglobulin as a treatment for BK virus associated nephropathy: one-year follow-up of renal allograft recipients. Transplantation 2006, 81:117-120.
6. Anyaegbu E.I., Almond P.S., Milligan T., Allen W.R., Gharaybeh S., Al-Akash S.I. Intravenous immunoglobulin therapy in the treatment of BK viremia and nephropathy in pediatric renal transplant recipients. Pediatr Transplant [Internet] Feb 2012, 16(1):E19-E24. [[cited 2012 Oct 1] Available from: http://www.ncbi.nlm.nih.gov/pubmed/22248251].
7. Schiff R.I., Williams L.W., Nelson R.P., Buckley R.H., Burks W., Good R.A. Multicenter crossover comparison of the safety and efficacy of Intraglobin-F with Gamimune-N, Sandoglobulin, and Gammagard in patients with primary immunodeficiency diseases. J Clin Immunol [Internet] Jan 1997, 17(1):21-28. [Available from: http://www.ncbi.nlm.nih.gov/pubmed/9049782].
8. Lomago J., Russell-Vaskov S., Lunz J., Martell J., Hunter B., Foster D., et al. 93-P analysis of HLA antibody titer and C1q binding capability in Privigen and Carimune IVIG preparations. Hum Immunol [Internet] Oct 2011, 72(null):S78. [[cited 2012 Oct 2] Available from:]. 10.1016/j.humimm.2011.07.118.
9. Solez K., Axelsen R.A., Benediktsson H., Burdick J.F., Cohen A.H., Colvin R.B., et al. International standardization of criteria for the histologic diagnosis of renal allograft rejection: the Banff working classification of kidney transplant pathology. Kidney Int 1993, 44:411-422.
10. Racusena L.C., Colvin R.B., Solez K., Mihatsch M.J., Halloran P.F., Campbell P.M., et al. Antibody-mediated rejection criteria - an addition to the Banff 097 classification of renal allograft rejection. Am J Transplant 2003, 3:708-714.
11. Haas M. C4d-negative antibody-mediated rejection in renal allografts: evidence for its existence and effect on graft survival. Clin Nephrol 2011, 75(4):271-278.
12. Mengel M., Sis B., Haas M., Colvin R.B., Halloran P.F., Racusen L.C., et al. Banff 2011 meeting report: new concepts in antibody-mediated rejection. Am J Transplant 2012, 12:563-570.
13. Hidalgo L.G., Campbell P.M., Sis B., Einecke G., Mengel M., Chang J., et al. De novo donor-specific antibody at the time of kidney transplant biopsy associates with microvascular pathology and late graft failure. Am J Transplant Off J Am Soc Transplant Am Soc Transpl Surg [Internet] Nov 2009, 9(11):2532-2541. [[cited 2012 Oct 2] Available from: http://www.ncbi.nlm.nih.gov/pubmed/19843031].
14. Jordan S.C., Tyan D., Stablein D., McIntosh M., Rose S., Vo A., et al. Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end-stage renal disease: report of the NIH IG02 trial. J Am Soc Nephrol JASN [Internet] Dec 2004, 15(12):3256-3262. [[cited 2012 Jul 25] Available from: http://www.ncbi.nlm.nih.gov/pubmed/15579530].
15. Vo A.A., Toyoda M., Puliyanda D.P., Lukovsky M., Bunnapradist S., Peng A., et al. Safety and adverse events profiles of intravenous gammaglobulin products used for immunomodulation: a single-center experience. Clin J Am Soc Nephrol 2006, 1:844-852.
16. Bollée G., Anglicheau D., Loupy A., Zuber J., Patey N., MacGregor D., et al. High-dosage intravenous immunoglobulin-associated macrovacuoles are associated with chronic tubulointerstitial lesion worsening in renal transplant recipients. Clin J Am Soc Nephrol 2008, 3:1461-1468.
17. Duronio A., Bajjoka I., Hsaiky L., Parasuraman R. Proposed relationship between intravenous immunoglobulin and thrombosis in renal transplant recipients. Ann Pharmacother 2007, 41:354-358.
18. Kahwaji J., Barker E., Pepkowitz S., Klapper E., Villicana R., Peng A., et al. Acute hemolysis after high-dose intravenous immunoglobulin therapy in highly HLA sensitized patients. Clin J Am Soc Nephrol 2009, 4:1993-1997.
19. Strong M., Lipton K.S. American Association of Blood Banks Bulletin #06-07 2006, 1-10.